| Name | Title | Contact Details |
|---|
Strategic Vision Inc is a Stedman, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
CCA Medical is a Greenville, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
New York Blood Center (NYBC) is one of the nation`s largest non-profit, community-based blood centers. NYBC has been providing blood, transfusion products and services to over 150 hospitals, serving 20 million people, in greater New York since 1964. NYBC is also home to the Lindsley F. Kimball Research Institute and the National Cord Blood Program at the Howard P. Milstein National Cord Blood Center, the world`s largest public cord blood bank. NYBC provides medical services and programs (Clinical, Transfusion, and Hemophilia Services) through our medical professionals along with consultative services in transfusion medicine.
Creganna is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnpod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 100,000 users across the globe rely on Insulet`s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com, www.myomnipod.com and https://www.omnipodeurope.com.* *Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long term, as it already does in the United States and Canada.